Cervical Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Cervical Cancer, including details on symptoms, vaccine, screening, treatment, human papilloma virus (hpv), information.

Volume 4 (2007), Issue 12 (December)

1. Where to look for the sentinel lymph node in cervical cancer.
   Am J Obstet Gynecol, 197(6): 678.e1-7. [Abstract] [Full-text]
2. Reducing the burden of glandular carcinomas of the uterine cervix.
   Am J Obstet Gynecol, 197(6): 566-71. [Abstract] [Full-text]
3. Stage IIB carcinoma of the cervix that is associated with pelvic kidney: A therapeutic dilemma.
   Am J Obstet Gynecol, 197(6): e8-10. [Abstract] [Full-text]
4. Tumor volume and uterine body invasion assessed by MRI for prediction of outcome in cervical carcinoma treated with concurrent chemotherapy and radiotherapy.
   Jpn J Clin Oncol, 37(11): 858-66. [Abstract] [Full-text]
5. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.
   Int J Cancer, 122(3): 486-94. [Abstract] [Full-text]
6. A 2-year follow-up study of anxiety and depression in women referred for colposcopy after an abnormal cervical smear.
   BJOG, 115(2): 212-8. [Abstract] [Full-text]
7. A longitudinal study of sexual functioning in women referred for colposcopy: a 2-year follow up.
   BJOG, 115(2): 205-11. [Abstract] [Full-text]
8. Fractionated grid therapy in treating cervical cancers: conventional fractionation or hypofractionation?
   Int J Radiat Oncol Biol Phys, 70(1): 280-8. [Abstract] [Full-text]
9. Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial.
   Int J Radiat Oncol Biol Phys, 70(1): 111-7. [Abstract] [Full-text]
10. Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment.
    Int J Radiat Oncol Biol Phys, 70(1): 118-25. [Abstract] [Full-text]
11. Cervical cancer regression measured using weekly magnetic resonance imaging during fractionated radiotherapy: radiobiologic modeling and correlation with tumor hypoxia.
    Int J Radiat Oncol Biol Phys, 70(1): 126-33. [Abstract] [Full-text]
12. Using the rate of positive high-risk HPV test results for ASC-US together with the ASC-US/SIL ratio in evaluating the performance of cytopathologists.
    Am J Clin Pathol, 129(1): 97-101. [Abstract] [Full-text]
13. The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial.
    Am J Clin Pathol, 129(1): 75-80. [Abstract] [Full-text]
14. Gene expression profiling to identify markers associated with deregulated hTERT in HPV-transformed keratinocytes and cervical cancer.
    Int J Cancer, 122(4): 877-88. [Abstract] [Full-text]
15. Human papillomavirus in cervical and head-and-neck cancer.
    Nat Clin Pract Oncol, 5(1): 24-31. [Abstract] [Full-text]
16. Comparative sensitivities of ThinPrep and Papanicolaou smear for adenocarcinoma in situ (AIS) and combined AIS/high-grade squamous intraepithelial lesion (HSIL): comparison with HSIL.
    Cancer, 111(6): 482-6. [Abstract] [Full-text]
17. Papanicolaou test interpretations of "atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion" : an investigation of requisite duration and number of colposcopic procedures to a definitive diagnosis of high-grade dysplasia in routine practice.
    Cancer, 111(6): 477-81. [Abstract] [Full-text]
18. Radiosensitizing effects of plumbagin in cervical cancer cells is through modulation of apoptotic pathway.
    Mol Carcinog, 47(1): 22-33. [Abstract] [Full-text]
19. Immune factors involved in the cervical immune response in the HIV/HPV co-infection.
    J Clin Pathol, 61(1): 84-8. [Abstract] [Full-text]
20. Effects of fixation on RNA integrity in a liquid-based cervical cytology setting.
    J Clin Pathol, 61(1): 132-7. [Abstract] [Full-text]
21. EGF upregulates Na+/H+ exchanger NHE1 by post-translational regulation that is important for cervical cancer cell invasiveness.
    J Cell Physiol, 214(3): 810-9. [Abstract] [Full-text]
22. MRgFUS for pain relief as palliative treatment in recurrent cervical carcinoma: a case report.
    Gynecol Oncol, 108(1): 241-3. [Abstract] [Full-text]
23. Initial experience with Dargent's operation: the radical vaginal trachelectomy.
    Gynecol Oncol, 108(1): 214-9. [Abstract] [Full-text]
24. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
    Gynecol Oncol, 108(1): 42-6. [Abstract] [Full-text]
25. Is frozen section analysis of pelvic lymph nodes accurate in locally advanced cervical cancer patients administered preoperative chemoradiation?
    Gynecol Oncol, 108(1): 220-5. [Abstract] [Full-text]
26. Adenovirus carrying TIMP-3: a potential tool for cervical cancer treatment.
    Gynecol Oncol, 108(1): 234-40. [Abstract] [Full-text]
27. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer.
    Gynecol Oncol, 108(1): 195-200. [Abstract] [Full-text]
28. Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings.
    Gynecol Oncol, 108(1): 154-9. [Abstract] [Full-text]
29. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years.
    Gynecol Oncol, 108(1): 106-11. [Abstract] [Full-text]
30. HPV+ cervical carcinomas and cell lines display altered expression of caspases.
    Gynecol Oncol, 108(1): 10-8. [Abstract] [Full-text]
31. Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy.
    Gynecol Oncol, 108(1): 126-9. [Abstract] [Full-text]
32. Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis.
    Gynecol Oncol, 108(1): 112-20. [Abstract] [Full-text]
33. Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation.
    Gynecol Oncol, 108(1): 19-26. [Abstract] [Full-text]
34. Extracapsular extension of pelvic lymph node metastases is of prognostic value in carcinoma of the cervix uteri.
    Gynecol Oncol, 108(1): 63-7. [Abstract] [Full-text]
35. Cervical cancer screening practices of certified nurse-midwives in the United States.
    J Midwifery Womens Health, 53(1): 11-8. [Abstract] [Full-text]
36. Significance of disease extent in high-grade cervical intraepithelial neoplasia excised with negative margins by loop electrosurgical excision procedure.
    Ann Diagn Pathol, 12(1): 17-20. [Abstract] [Full-text]

© 2004-2008 Cervical Cancer Research Today. All Rights Reserved.